Trial Information
Dose Escalation Study of the Combination of ZD6474, Gemicitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Inclusion Criteria:
- Confirmed diagnosis of locally advanced unresectable or metastatic pancreatic
adenocarcinoma
- ECOG performance status <1
- Measurable disease
Exclusion Criteria:
- Severe or uncontrolled systemic disease
- Clinically significant cardiac event such as myocardial infarction
- Any concomitant medication that may cause OTc prolongation, include Torsades de
Pointes
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Define Maximum Tolerated Dose (MTD)
Outcome Time Frame:
during whole study
Safety Issue:
Yes
Principal Investigator
Piercarlo Saletti, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Bellinzona, Switzerland
Authority:
Switzerland: Swissmedic
Study ID:
D4200L00003
NCT ID:
NCT00681798
Start Date:
July 2006
Completion Date:
June 2009
Related Keywords:
- Pancreatic Cancer
- pancreatic cancer
- pancreatic adenocarcinomina
- pancreas cancer
- dose escalation study
- locally advanced unresectable pancreatic adenocarcinoma
- Zactima
- Vandetanib
- ZD6474
- Adenocarcinoma
- Pancreatic Neoplasms